The selection of a starting dose for an antidepressant, and subsequent clinical titration to an appropriate therapeutic dosage, should be based on pharmacokinetic and pharmacodynamic principles. In the past decade, therapeutic monitoring of antidepressant drugs and use of pharmacokinetic principleshave been shown to be an improvementover the dose-response approach. Endogenous(e.g., genetic metabolic phenotype, hepaticblood flow, and proteinbinding)and exogenous factors (e.g., smoking, dietary habits, concurrent medications) are capable of influencingphysiological and pharmacokinetic variables in patients, accounting for the marked interindividual differences in the clearance rates of cyclic antidepressants. lnterpatient variability for steady-state concentrations in plasma (Cpss) >20-fold are observed at a fixed dose of imipramine(r2 = 0.525, df = 346, 1= 19.541, P <0.0001) or doxepin (r2 = 0.506, df = 128, 1 = 11.403, P <0.0001). Analysisof doxepinin plasmavs estimatedIn oral clearance for 61 patientsdemonstratesa significantdecline inoral clearanceas a functionof Cpss. At dosesapproaching the upper range recommendedfor the treatmentof depression, Cpss appear to approach, in at least a few individuals, the maximummetaboliccapacityof the patient (V), leading to greater-than-expectedincreasesin concentrationsfor a given dosage increment. Significant alterations in oral clearance are observedwhen medicationsare administered concomitantly.A greater-than-threefolddifference in mean oral doxepin clearance rates is observed between two groupsof patientsreceMng additionalmedicationsthat are eitherinducersor inhibitors(P <0.0001, df = 32, 1= 6.687). Pharmacokineticprinciplesdefiningand explainingthe determinants of oral clearance can provide the clinician with a greater insight into the reasons for therapeutic failure and toxicity.
toring of antidepressant drugs and use of pharmacokinetic principles have been shown to be an improvement over the dose-response approach (3).
Numerous studies have illustrated the weak correlation
between the administered dose of a cyclic antidepressant and the resulting concentrations in plasma, and the considerable interindividual variability (4). Endogenous (e.g., metabolic phenotype, hepatic blood flow, and protein binding) and exogenous factors (e.g., smoking, dietary habits, concurrent medications) are capable of influencing physiological and pharmacokinetic factors in patients, accounting for the marked differences in the clearance of cyclic antidepressants (5) (6) (7) (8) (9) . As a result of the interaction of the above processes, it becomes apparent that the relationship between dose and the concentration in plasma (CP) can be quite dynamic and unpredictable, leading to extremely large interindividual differences in steady-state drug concentrations in plasma (Cpss). The application of pharmacokinetics to dosage selection can significantly increase the likelihood of a successful treatment outcome, because concentration vs response relationships for many of the TCAs have been documented (10). for plasma sample handling and data collection. All patients who had TDM ordered by their physicians are included in our data base. All patient data are coded, to protect confidentiality. The results of our initial analyses of the doxepin (DOX) and imipramine (IMI) TDM program in 212 patients are reported (see Table 1 samples are rapidly centrifuged and the plasma is stored in Teflon-capped glass tubes; plasma is stored at room temperature but protected from light; and samples are shipped by mail and analyzed within two to three days of collection.
Materials and Methods

This review
The standard data-collection form, required to be completed before assay, contains the following information: patient demographics (age, gender, weight, race, smoking history); medical and psychiatric diagnoses based on the Diagnostic and Statistical Manual, 3rd edition, revised; complete medication history for at least the past week, including dosing history for the agent to be assayed and all concomitant medications; and the Clinical Global Impressions Rating Scale. Outpatient data, primarily from the one county facility, are included in the data set, but >80% of all concentrations are measured in inpatients, who are receiving their medications from the facility's nursing service. Data are stored in a microcomputer data base and are available for downloading.
The TCAs are analyzed by a validated "high-performance" thin-layer chromatographic method developed by The University of Texas Mental Sciences Institute (11). Sensitivities by this method are as low as 5 ng/mL (for desipramine). The standard curves used for routine analysis are linear from 5 to 200 ng/mL. Between-day coefficients of variation (CVs) are <6% from 25 ng/mL to 200 ng/mL. For in situ quantification of the developed chromatographic plates we used a Zeiss or a Shimadzu scanning densitometer. Measurements were made in the reflectance mode for ultraviolet absorption. A deuterium light source was used with a monochromator and set to the optimum wavelength for each TCA. Figure 2 illustrates the mean of and standard deviation for Cpss of IM.! plus desipramine (DM1) in 25 patients from whom two or more samples were obtained at the same dosage of IMI. These data illustrate the reproducibility of the assay under field-test conditions, because variability in the observed concentrations is the result of patient-specific variables (e.g., compliance, potential timing errors by nursing stafi) as well as the variability inherent in the assay.
The data were analyzed with a Macintosh U#{174} microcomputer with 68020 and 68881 processors, with use of StatView 512K plus#{174}, and Microsoft Excel#{174} spreadsheet. They were plotted by using MacDraw#{174}, Cricket Graph#{174}, and SuperPaint#{174}. Statistical analyses of data included: Pearson product moment correlation analysis for linear regression, polynomial regression, Student's unpaired two-tailed t-test for comparison of normally distributed variables, analysis of variance for evaluation of independent categorical variables, and natural log transformation of clearance data. The mean of two or more CPs at the same dose was used for data analysis, decreasing weighting artifacts. The following guidelines were used as the criteria for deleting data from the unedited data-base output before statistical analyses: (a) if one CP differed by more than 50% from the mean of two other concentrations at the same dose; (b) if for outpatient data two CPs at the same dose differed by more than 50% (presumed noncompliance); (c) if patients had unstable medical illnesses; (d) if toxicity secondary to overdose or medication error was documented; or (e) if one of two CPs at the same dose was not detectable (typically at the lower limits of the assay) but the other was quantified. The classification scheme used for drug interaction effects on clearance secondary to concomitant medications are summarized in the Drug Interactions section of this paper.
Results
Pharmacokinetic
Overview of the Antidepressants Figures 3 and  4 demonstrate the large interpatient variability on standard dosages of DOX and IMI, respectively. These data include all patients examined, and do not control for drug interactions. A large proportion of patients have CPs that are known to be associated with either a poor therapeutic outcome or an increased incidence of side effects/toxicity. The modest correlation coefficients suggest that the dosage alone is a poor predictor of CP.
To decrease the potential confusion resulting from the widely varying conventions used for abbreviations and symbols in pharmacokinetics, standardized nomenclature has been proposed. Table 2 lists widely accepted terms used to characterize pharmacokinetic models of cyclic antidepressanta (19) .
A review of pharmacokinetic parameters,
with illustrations of their clinical application and significance, suggests that cyclic antidepressants have many similarities. The following discussions of absorption, first-pass effect, distribution, and hepatic clearance highlights the relevant siinilarities and differences between antidepressants.
Absorption
Phy8icochemical: Cyclic antidepreasants are basic lipophilic amines whose absorption is believed to take place in the alkaline environment of the small intestine. There is little or no absorption across biological membranes at the acidic pH of the stomach, owing to ionization of the drug. Absorption has been shown to be almost complete for all cyclic antidepressants except maprotiine (20) , as assessed from analytical recovery and measurement of all urinary metabolites.
Absorption rate: Absorption of TCAs such as IMI is relatively rapid, with the peak CP (Cp,,.,) within 2 to 8 h after a single oral dose (21,22) or after multiple doses(23). The newer antidepressants show a greater diversity in their absorption characteristics than do the TCAs. For instance, maprotiline's absorption is slow, with Cp,, occurring 8 h or more after a dose (24) . Being a relatively strong base with a reported Pta of 10.5 (in water), maprotiline is almost completely protonated at physiological pH and therefore penetrates lipophilic barriers relatively slowly. Protriptyline also has a slower absorption proffle, with a time to peak concentration (Tm) averaging 8.5 h, with range of 6 to 12 h (25) .
Bioavailability factor (F)
. This is the fraction of the orally administered dose that reaches the systemic circulation. After absorption from the gastrointestinal tract, drugs must pass through the liver, along with the entire blood supply draining the upper gastrointestinal tract, where some of the drug is lost by metabolism before reaching the systemic (general) circulation. This is known as the "first-pass" effect. This first-pass metabolism or extraction accounts for most of the dose of TCA that is "lost" (26) . This large first-pass effect accounts for the low systemic bioavailability (F = 0.2 to 0.7) of the TCAs, in spite of their complete absorption. Table 3 summarizes pharmacokinetic parameters for cyclic antidepressant agents, including the range of bioavailabiities reported for each drug. Protriptyline and maprotiline demonstrate higher bioavailability (F = 75%-90%), with an estimated metabolism on first pass through the liver of only 10% to 25% of the oral dose. On the other extreme, DOX seems to be least bioavailable, with F between 13% and 45% (27) .
F can be described both in terms of the extraction ratio 
40-105
(E), the proportion of the blood flowing through the liver that is cleared of the drug, and in terms of the ratio of the area under the CP vs time curve (AUC) for oral and parenteral administration as illustrated by the following equation:
The determinants of hepatic clearance also influence a drug's bioavailability.
A more scientific approach to drug dosage adjustment results from an understanding of these pharmacokinetic parameters. In general, drugs with E >0.6 will have a low F, and vice versa. These high-hepatic extraction drugs have a large intrinsic hepatic clearance (CL,,,). Elimination ofdrugsfrom the body is usually described in terms of clearance (CL), which is defined as the volume of plasma cleared of drug per unit time. Because renal excretion of drug is negligible for TCAs, total CL is equal to hepatic CL (CLH). The determinants of CLB can be described as follows:
Equation 3 indicates that the systemic CL of a drug that is eliminated solely by metabolism in the liver is a function of hepatic blood flow, Q,the fraction of the drug that is unbound in plasma, f, and the intrinsic ability of the liver to metabolize the drug. For drugs with a low E and hence a low CL-e.g., barbiturates and anticonvulsants-Q is much greater than CLtht, and it follows that equation 3 reduces to:
For these drugs, CL,,5 is the principal determinant of systemic CL. it is not surprising, then, that certain diseases or concomitant drugs that inhibit or induce enzymes in the liver will affect the systemic CL of low-E drugs. Figure 5 illustrates the possible effect on the oral CL of TCAs of a concomitant disease, that alters hepatic blood flow and function. This case of a 57-year-old woman receiving IMI and who had moderate to severe congestive heart failure, subsequently digitalized with returnofnear-normal cardiac output, demonstrates an increase in her oral clearance ratefrom 0.5 L/min to 0.9 Ijmin.
Alternatively
In general, the systemic CL ofdrugs that show hepaticblood-flow dependentelimination isaffected by factors such as cardiacand hepaticdiseases or concomitantmedications that affect the cardiovascular system. these drugs depends less on factors that affect drug-metabolizing enzymes in the liver. However, the magnitude of the first-pass effect will be affected by the enzyme-metabolizing activity of the liver, even for drugs that show flow-dependent elimination. Therefore, a decrease in the drug's F would result from the co-administration of an enzymeinducing agent, resulting in a measured increase in oral CL (seeDrug Interactions section).
Although cyclic antidepressants in general have intermediate E values, there are certain exceptions. Maprotiline and protriptyline both have an F between 0.75 and 0.90, hence they will have a low E (0.10-0.25). Theoretically, these drugs should be more susceptible to changes in systemic CL, owing to enzyme induction or inhibition, and less likely to demonstrate CL changes caused by hepatic blood-flow alterations. Most cyclic antidepressants such as AMI have E values ranging between 0.4 and 0.70, indicating that both hepatic blood flow and first-pass effects will contribute to CL variability.
Food. Unlike JMI (28) , where food seems to have no effect on F, Cp.., and T,,, trazodone's absorption is delayed by food, with a decrease in the Cp,,. However, no effect on the AUC is observed (unpublished data, Mead Johnson).
Distribution
Cyclic antidepressants are very soluble in fat and so are extensively distributed in tissue, resulting in large volumes of distribution (IT), up to 63 11kg, with great intersubject variability (seeTable 3). Like TCAs, most of the newer cyclic compounds behave as lipophilic bases, with concentrations in tissue exceeding that in plasma in animal studies, e.g., maprotiline (29) , amoxapine (30), trazodone (31), and bupropion (32). Therefore, hemodialysis or hemoperfusion may not be successful in removing these drugs after an overdose. The animal data of Bickel et al. (33) showed that the highest concentrations of IMI were found in the lung, kidney, brain, small intestine, liver, skeletal muscle, and skin; the lowest concentrations were in plasma and adipose tissue. These experimental data imply that adipose tissue may not be the site of sequestration of antidepressants and suggeststhat significant decreases in clearance may not be observed in most obese patients. A weak relationship (r2 = 0.251, dl = 61, t = 4.49, P <0.0001) between weight and DOX CL is observed: DOX oral CL = 0.069 weight (kg) -1.914. One patient with morbid obesity had a DOX CL rate twice that of any other patient. For 1M1 no significant relationship is observed between these two parameters (r2 = 0.055, dl = 139, t = 0.0642, NS).
Metabolism/Excretion
Cyclic antidepressants are metabolized almost entirely by the liver. Of the administered dose, <5% is excreted unchanged in the urine (34). The major metabolic pathways are oxidation and conjugation; N-oxidation and dealkylation are minor pathways. Side-chain N-demethylation and hydroxylation in the ring structures are the most important routes of metabolism. Hydroxy metabolites are then conjugated before being eliminated in urine and bile. There is very little evidence of metabolism in the gut wall; however, some evidence exists for biiary excretion and reabsorption, i.e., enterohepatic circulation (35).
Of the tricyclics, IMI is the most extensively studied. Figure 6 illustrates the metabolism of IMI via hepatic demethylation (yielding DM1) and hydroxylation (2-hydroxy-IMI and 2-hydroxy-DMI). DM1 can be further demethylated to the primary amine, didesmethylimipramine. Biotransformation of the other tricyclics are analogous to that of IMI, with few variations. Table 4 lists the active metabolites of TCAs, and the metabolite to parent drug concentrations at steady state.
Occasionally, oxidative metabolism can alter the pharmacological proffle of the metabolite or significantly alter pharmacokinetic properties, accounting for adverse effects not associated with the parent compound. As an example, hydroxylation primarily accounts for amoxapine metabolism, producing 7-hydroxyamoxapine and 8-hydroxyamoxapine. The 7-hydroxy compound, although present in plasma in extremely low concentrations (1-5 ng/mL), has neuroleptic effects comparable in potency to those of haloperidol (36). The 8-hydroxy metabolite, which exceeds the CPs of the parent compound at steady state, owing to its longer elimination half-life, accounts for most of the antidepressant activity (37). Trazodone's metabolism, in addition to hydroxylation, includesN-oxidation to an active metabolite, mchiorophenylpiperazine. This metabolite, in contrast to trazodone, isa direct serotonergic agonist, acting mainly at the postaynaptic receptors rather than by presynaptic reuptake blockade (38). Fluoxetine is demethylated hepatically to its active metabolite norfluoxetine, which has a much longer half-life, in the range of seven to 15 days (39). Therefore, the time required to reach Cpss can exceed a month. Maprotiline's principal metabolite is the desmethyl derivative, which accumulates to reach substantial proportions upon chronic administration, owing to its long half-life (29) . Early reports of increased risk of seizures at therapeutic dosages might have been secondary to rapid dose titration (without accounting for the greater accumulationof desmethylmaprotiline).
For TDM, do all active metabolites of an administered drug need to be quantified?
Most cyclic antidepressants have metabolites that are pharmacologically active and that penetrate the brain. Therefore, routine TDM assays will always measure the demethylated metabolites of TCAs, e.g., the sum IMI and DM1 are reported when an IMI CP is measured. Attempts have been made to assessthe relationship between clinical effect and concentrations of hydroxy metabolite. However, limited data are available, because clinical studies of the administration of hydroxy metabolites in patients are lacking. Different antidepressants have different ratios of hydroxy metaboliteto parent drug (see Table 4 ). In one study, measurement of the concentration of 2-hydroxy DM1 alone did not provide as useful a correlation with response as did assay of DM1 (40). The combination of the parent and its hydroxy metabolite did not improve the correlation over that seen with DM1 alone. The role of the hydroxy metabolites in adverse effects or efficacy is as yet unclear, and there is little justification for routinely assaying them (43) .
If metabolic conversion is constant for most patients over the dosage range used, then the measured concentrations of the tertiary-and (or) secondary-amine TCAs should be proportionately representative of the hydroxy metabolites' CPs. Although this appearstobe true, the large interindividual variability observed in the ratio of parent to metabolite suggests that a few patients may have atypical metabolic patterns (e.g., they may be slow hydroxylators), leading to potentially clinically significant differences in how TDM results should be interpreted (see Nonlinear
Kinetics and Pharmacogenetics sections).
Data generated from our TDM program for doxepin and IMI support a linear kinetic model based on the population relationship between the administered dose and the CP (see Figures 3 and 4) . However, the correlations for dose vs observed concentration are modest, indicating that Cpss cannot be predicted from dosage alone. Interpatient variability for Cpss >20-fold is observed at a fixed dose of IMI (r2 0.525, dl = 346, t = 19.541, P = <0.0001) or DOX (r2 = 0.506, dl = 128, t = 11.403, P <0.0001). Additionally, the strong correlation (r2 = 0.848, dl = 32, t = 13.56, P <0.0001) found between DOX and desmethyldoxepin Cpss in 34 patients with no known interacting drugs over a wide concentration range suggests that demethylation does not reflect saturation. In contrast, the ratioofDOX to desmethyldoxepin Cpss in all patients in the data base varies widely over the dosage range of 25 to 300 mg/day (r2 = 0.024, dl = 73, t = 2.01, P = 0.13). The linear regression-derived equation for this ratio of Cpss = -0.002 dose + 1.491, demonstrates a slope-zero relationship with extremely high interindividual variability. Concomitant medications, concurrent illness, age, and endogenous characteristics such as V and CL account for much of the variability observed in the above relationships. The section on Drug Interactions explores how controlling for category of concomitant medication can improve correlations between dose and Cpss.
Interpretation of Antidepressant CPs
Within the dosage range recommended by the manufacturers, cyclic antidepressants have been described as pharmacokinetically linear-i.e., the amount of drug absorbed or eliminated over time is directly proportional to the amount available for these processes (5). This proportional relationship between dose and CP means that changes in drug doses will produce changes in Cpss that bear a constant (linear) relationship to the dosage changes. It is the premise upon which all dosage predictions and titrations are based. The pharmacokinetic behavior of these drugs can be described by the following formula:
Clearance is the product of the rate of elimination (k) and V. In normal situations, the only term in the equation that changes with an increase or decrease in dose is Cp00av (the average steady-state plasma concentration). Tau (r) is the dosing interval. Thus, with all other terms being constant (a), the equation can be rearranged as:
Therefore, from equations 6 and 7 a proportionality can be set up equating a target CP with an estimated dosage to achieve this concentration: new dose = present dose (target Cpss/present Cpss), e.g., double the dosage to double the CP. The elimination rate is therefore assumed to be constant for all concentrations of drug and is related to half-life (tm) by equation 8:
For antidepressant drugs, k is almost entirely controlled by hepaticmetabolism.The t, a clinically useful pharmacokinetic parameter, is used to characterize the rate of accumulation and decline of drug in the body. The time required to attain Cpss from chronically administered doses of medication depends on k and can be estimated as 4 to 5 x t. CPs, except of cases of toxicity, should be obtained at steady state, to ensure accurate interpretation and safe application to dosage adjustment.
Concentrations in Plasma: Relation to Dosage Schedule and Sampling Time
Standardization of sampling times and interpretation of CPs of cyclic antidepressants in relation to dosage schedule is a requirement for TDM. There have been few studies investigating the stability of Cpss of cyclic antidepressants during the 24-h dosing interval. Kragh-Sorensen et al. (45) examined the effect of a single dose of NT on steady-state concentrations and found little change in CP during the subsequent 8 h. Additionally, studies with NT or AM! have both yielded comparable CP (post-distribution phase) in volunteers receiving the drug on either a "three times daily" or "at bedtime" dosage schedule. Overall, the mean CPs were stable (within 20%) during the sampling period and similar on the two schedules (44, 45) . Studies with IMI and DM1 also showed similar results, with relatively stable CPs on both dosage schedules. No significant differences have been found between dosage schedules and the therapeutic effectiveness or severityof side effects of TCAs (9). The observed differences of up to 20% to 30% in the Cpss on different dosage schedules that have been reported might not be significant with regard to TDM, especially if the assay's CV is 10%.
Although uniformly spaced doses throughout the day are comparable to at bedtime only, patients on other, special dosing regimens can show significant differences in Cpss measured at the same daily dosage. Figure 7 illustrates the increased variability present in Cpss in a patient in our TDM program receiving IMI four times daily (8a.m., noon, 4 p.m., and 8 p.m.) vs at bedtime only. Note that the 100-mg bedtime dose of TM! produces values for Cpss exceeding those obtained with 30 mg four times daily.
Binding by Protein
Protein binding is another important factor in the deter-00 mination of the concentration of the active drug-free fraction or ft-available at the receptor site. For most drugs, only a small portion of the total amount in the body is freely diffusible in the aqueous portions of the circulation and the extravascular tissue. It is generally believed that it is this freely diffusible drug that is in equilibrium with the receptor site and relates to the onset, magnitude, and duration of the pharmacological and toxicological effects.
Reversible drug binding can be represented as follows:
where DF is free drug, S is a free binding site, and DB is bound drug. This leads to the relationship of DB to DF as follows:
where S is the total concentration of binding sites (capacity) and K is the equilibrium dissociation constant (inverse affinity).
In plasma, drugs are usually bound to blood constituents, particularly to plasma proteins. Acidic and neutral lipophilic compoundstend to bind to albumin; basic compounds such as cyclic antidepressants and certain neutral compounds bind to a1-acid glycoprotein, lipids, and cholesterol. Changes in the concentration of binding substances can influence V, CL, t01,Cpss, and DF. Thus increases in them can decrease hepatic metabolism or renal excretion, because only the unbound fraction of the drug is available to the metabolic or excretory sites.
Protein binding of cyclic antidepressants is highly variable, ranging between 68% and 98%. Binding to albumin, a1-acid glycoprotein, plasma lipids, and erythrocytes (46) occurs with a range of affinities as well as capacities. According to one study (47) , a physiological concentration (0.67 g/L) of isolated a1-acid glycoprotein in water bound 69% of the IMI with high affinity. Piafsky and Borga (48) reported a negative correlation between the free fraction of IMI and the concentration of a1-acid glycoprotein, but no correlation between the IMI f and albumin concentration in plasma. These data suggest that aj-acid glycoprotein may play an important role in determining the degree of binding in plasma. In one study, the use of ultrafiltration techniques yielded an f of IMI of 7.9% (48), whereas in another the mean f was only 4.2% (49) . These large interindividual differences in free fraction might result in correspondingly large differences in the total CP vs clinical effect relationship for a specific patient. However, differences in methodologies used to determine D can explain part of the observed variability between studies. The degree of binding of cyclic antidepressant might also change over the course of therapy, with one study reporting a decreased free fraction secondary to increased a1-acid glycoprotein concentrations (50). Being one of the "acute-phase reactants," aj-acid glycoprotein concentrations in plasma are known to increase in short-and long-term inflammation, malignancy, "stress," and in various hematological conditions, possibly resulting ina decrease in f. Alternatively, a1-acid glycoprotein will tend to decrease in hepatic disease, nephrotic syndrome, pregnancy, malnutrition, and with the use of oral contraceptives, resulting in a higher f (48). A change in lipoprotein can also affect binding of antidepressants, as exemplified by increased binding of IMI in patients with hyperlipoproteinemia (51). When a drug in plasma is displaced by another drug, the f can increase, which increases V. Because Cpss is proper- equation 6) , it follows that a change in binding might affect relative concentrations of total and free drug. For a medication with a low E, an increase in f increases the CL of a drug, resulting in a decrease in Cp,av. However, DF remains unchanged, because the displacer drug increases f. Therefore, no change in maintenance dosing would be needed, even though Cp8,av might change.
For drugs with a large E, Cpss would not be altered by the addition of a displacer or decrease in binding-protein concentration (assuming an intravenous route of adininistration), because CLH is limited primarily by Q(see equations 3,4, and 5). However, changes in binding of orally administered drugs with moderate to large E by a displacer-e.g., cyclic antidepressants-can result in changes in Cpav and f that resemble low-E drugs. One of the reasons for this difference between intravenous and oral routes of administration is a decreased F, owing to greater first-pass metabolism of the orally administered drug. First-pass metabolism is influenced by changes in f despite the high E (i.e., Qdependent systemic CL). However, the large V of the TCAs decreases the total potential change in measured CPs secondary to binding-site changes. To illustrate the relative unimportance of drug interactions for cyclic antidepressants, which aresecondary to changes in f11, caused by drug displacement, consider this worst-case scenario: f1, in plasma = 10%, V 40 L (an underestimate), and a plasma displacer capable of causing f to approach 100%. Re-equilibration of drug into the large reservoir of tissue occurs rapidly, resulting in a marked reduction of CP so that D is only 5% to 10% greater than the concentration at baseline (52). Only immediately after a displacer is given would there be a significant risk for increased adverse effects. Table 5 summarizes the effects of protein-binding/drug-displacement interactions for orally administered medications with various pharmacokinetic properties.
Therefore, depending on a drug's pharinacokineticproperties, TDM results might not accurately reflect the concentration of pharmacologically active medication. Additionally, TM! protein-binding studies have shown up to a fourfold interindividual variability in free fraction (49, (53) (54) (55) . Therefore, the differences in f0 between patients might be of sufficient magnitude to reduce the robustness of Cpss vs response relationships in these few individuals with DF at the extremes of the distribution for the population. TDM of TCAs for most patients should not require adjustment of the therapeutic range if binding proteins are known to be decreased or if a displacer drug is added (see Table 5 ).
It is unclear whether or not measurement of free-drug concentration would help improve the quality of TDM. Although many studies have investigated the relationship between CPs of antidepressants and efficacy, only a few studies have examined the relationship between DF and clinical response, because the methodologies are limited. Equilibrium dialysis is cumbersome, and ultrafiltration techniques may result in lossof drug secondary to binding to the ifitration devices (27) . In addition, the concentrations of free antidepressants (3-20 ng/mL) are typically below the usual detection limits for most assays. Free AM! concentration did not seem helpful in explaining the relationship between CPs and clinical response in one study (41). However, in another study, free NT concentrations >10 nglmL tended to correlate with poorer response in patients treated for three weeks, whose Cpss were between 50 and 150 ng/ mL (42) .
Prospective Dosing
There are significant differences in cyclic antidepressant CPs among patients who are receiving the same dose of a given drug. Monitoring of CP partly resolves this problem, but traditional TDM approaches require that sampling be obtained at steady state. A desirable goal might be to try and individualize drug-dosage regimens at the onset of treatment. This idea was first implemented by Alexanderson and colleagues (56-58) in studies performed on healthy volunteers. Results for DM1 and NT showed an excellent correlation between drug clearance after a single oral dosage and that obtained after repeated medication.
The possibility of predicting individual dosage regimens One method used to make a prospective dosage prediction is to calculate an abbreviated area under the curve (AUC) from several timed blood samples obtained during the drug's beta-elimination phase: The maintenance dose required to achieve a desired Cpss can be estimated with the equation (62, 63) , and NT (10, (63) (64) (65) (66) (67) . All of these investigators reported high correlations between post-dose test CP (obtained between 12 to 72 h after the test dose, dependingupon the study) and those achieved at steady state. In some of these studies, a nomogram was constructed to allow the dosage to be adjusted from the test level (67) .
The first prospective studies of TCA dosage prediction were not done until 1980. When the abbreviated AUC method was used to predict the Cpss of DM1, a strong linear correlation (r = 0.97; P <0.001) was found (61). Similarly, Dawling et al. (64) used this abbreviated AUC method to predict steady-state NT CPs, but did not find as good a correlation (r = 0.71; P <0.002).
As an illustration of the application of the single-dose, single-point technique, in a prospective study using the 24-h CP of DM1 (concentration measured 24 h after administration of a single dose of the drug) to predict its Cpss, Potteret al. (61) found a moderately strong relationship (r2 = 0.84; P <0.01) between predicted and observed levels. These studies (66, 68, 69) also demonstrated that it is possible to predict Cpss for NT from a single blood sample taken 24,48, or 72 h after a single oral-test dose with comparable correlative strength to those previously reported in the area-under-thecurve method. In addition, the estimation of a therapeutic dose using this single-point technique is reported to be superior to the method in which the t1,, in plasma is calculated (69). Any single-point method for predicting Cpss will be limited by the accuracy with which the method measures low concentrations. Studies by Dawling et al. (64) indicated that, for TCAs, greater predictive power is achieved from single-test CP measured at 72 h than at 24 h. In addition, predictions will be influenced by the stability of clearance over time-e.g., by extraneous factors that transiently influence concentration, such as alcohol consumption within 24-48 h of the procedure.
There might also be significant departures from predicted values, if the relationship between dose and Cpss over the usual concentration range used for depression is not linear (dose-dependent kinetics).
Nonlinear Kinetics
TCA Cp have been used to guide dose adjustment, and recently 24-h CPs have been advocated for predicting therapeutic doses.Both these methods of dose adjustment assume linear drug kinetics. Over the past few years, however, there have been numerous reports that suggest nonlinearity in antidepressant pharmacokinetics. In some patients a dose increase results in a disproportionately high increase in the Cpss. In 1979, Amsterdam et al. (5) reported a 14-fold increase in plasma DM1 when the dose was tripled. A retrospective review of the records of all patients who had TCA Cpss determined while on two different dosages revealed apparent nonlinear kinetics with DM1, but not with AM! (70). The investigators attributed this lack of observed nonlinearity in AM! kinetics to differences in metabolic pathways. There is evidence that N-demethylation and Chydroxylation of a drug are independent pathways; for example, N-demethylation of antipyrinedoes not correlate with metabolism of debrisoquine, a drug commonly used to assess hydroxylator status. Diminished metabolism of debrisoquine is associated with impaired 2-hydroxylation of DM1 (71). Moreover, the TCAs share the same hydroxylation pathway as illustrated by the inhibition of AM! hydroxylation by NT. Demethylation may be the rate-limiting step in the metabolism of a tertiary tricyclic TCA such as AM!, in contrast to hydroxylation being rate limiting for secondary amines.
This dose-dependent phenomenon has been reported by others: one case was an elderly patient, whose three sisters also have a metabolic defect (72), and another was a 44-year-old patient who was subsequently determined to be a slow debrisoquine hydroxylator; these demonstrate the phenotypic variables (71). The first prospective study on the nonlinear kinetics of DM1 and 2-hydroxy DM1 was done by Cooke et a!. (73) . They demonstrated that in six patients who completed 21 days of fixed-dosage treatment, 150 mg per day, and who were then placed on 250-300 mg per day for an additional week, a disproportionate increase in normalized DM1 and 2-hydroxy DM1 concentrations was found. In another prospective study, 11 of 42 patients demonstrated linear DM1 kinetics with ratios of Cpss to low vs high doses of 1.02 or less (74). In a third of the sample (14/42), concentrations increased by 50% more than expected, and in four of the 42 patients, concentrations increased twice as much as would be predicted by a linear relationship. These patients had low initial concentrations, with low estimated Km (Michaelis-Menten rate constant), suggesting rapid drug clearance at low dosage (74). Nonlinear kinetics have also been reported with TM! (75-77), NT (78), DOX (79), and AM! (80). Brosen et al. (77) , in a prospective study, found that there was an increasing DMII!M1 Cpss ratio with increasing IM1 dose and age. There was also a highly significant correlation between 2-hydroxy DM1/TM! Cpss and 2-hydroxy DMIIDMI Cpss ratios, which suggests that the hydroxylation metabolic step had become saturated.
In our analyses of the Cpss of various TCAs, we have found individual cases of nonlinearity for DOX, IMI, and DM1. An ifiustrative case is depicted in Figure 9 for TM!. Additionally, a plot of DOX Cpss vs In DOX oral CL for 61 patients (Figure 10 ) demonstrates a significant decline in oral CL as function of Cpss. Therefore,at doses that approach the upper range used in clinical practice, Cpss appear to approach-in at least a few individuals-the maximum metabolic capacity of the patient (V), leading to greater than expected increases in concentrations for a given increase in dosage.
Decreased hepatic biotransformation of TCAs to the hydroxy metabolite at higher CPa seems to be frequently observed but not widely appreciated by clinicians. Interestingly, other multicydic compounds that are hydroxylated by the cytochrome P-450 system, such as phenytoin, are well documented to demonstrate nonlinear Michaelis-.Menten model kinetics (81).
Drug Interactions
Drug interactions further confoundthe clinician's ability to predict CP based on dose, and they complicate the doseresponse relationship observed with antidepressant therapy. Such interactions can alter a given cyclic antidepressant's pharmacokinetic and pharmacodynamic profile. Pharmacokinetic interactions can occur at many different levels: gastrointestinal absorption, metabolic degradation, renal clearance, and changes in distribution caused by protein-binding displacement. Changes in these variables may alter the concentrations of the drug in the plasma and (or) at the site of action, modulating both intensity and duration of effect. The pharmacodynamic interaction of two concomitantly administered agents at the same receptor site can enhance or diminish therapeutic effects. The sum of these interactions will determine whether a drug will antagonize or potentiate the effects of another.
Drug interactions based on changes in gastrointestinal absorption are not well documented for TCAs. Gastrointestinal motility, transit time, and physicochemical interactions such as adsorption or solubility changes are not documented in the literature, suggesting that they are not clinically significant. Differences between two generic or branded drug's formulations can lead to significant intra-individual alterations in the F and absorption rate (82).
A drug that affects the glomerular excretion or tubular reabsorption of another medication that is renally eliminated can alter the rate of CL of the latter. For cyclic antidepressants renal clearance of unchanged drugs is negligible. However, after a single dose of TM!, up to 8% is excreted as the metabolite 2-hydroxy DM1. Therefore, a potential exists for accumulation of active metabolites in patients with changes in renal function secondary to disease or a concomitantly administered drug. Medications affecting the metabolic enzyme systems can interact with cyclic antidepressants on both the pharmacokinetic and the pharmacodynamic levels. For instance, monoamine oxidase inhibitors, when combined with TCAs, potentiate their pharmacological action, leading to increases in adverse effects and therapeutic efficacy in refractory depressed patients. Agents that either stimulate or inhibit the nonspecific cytochrome P-450 mixed-function oxidase system in the hepatocyte may cause metabolic drug interactions. Additionally, based on equations 1-5, alterations in plasma protein binding and hepatic blood flow may alter the drug's CL. The magnitude of this change in CL depends on the characteristics of the antidepressant (high vs low E). Interactions that most significantly increase CLH of cyclic antidepressants involve direct stimulation of the oxidative system by another drug or chemical, e.g., phenobarbital, carbamazepine, rifampin, phenytoin, and compounds ingested as a result of cigarette smoking. The pattern of microsomal isoenzymal induction differs between compounds such as phenobarbital and polycyclic hydrocarbons. The interval before onset of induction varies, ranging from within two days (for, e.g., rifampin) to a week (for, e.g., phenobarbital). Maximal enzyme induction for these drugs can take two or more weeks, leading to a lag period for maximal change in CL of cyclic antidepressants (83, 84) . The magnitude of this drug interaction effect is illustrated in Figure 11 . The patient, while at steady state on IMI, 150 mg/day, and alprazolam had a combined Cpss for IMI plus DM1 of 465 ng/ mL. After being placed on IMI, 200 mg/day, carbamazepine was initiated and maintained for two weeks before the next CP. Despite the 33% increase in dosage, the Cpss decreased by 23% to 360 ng/mL. Changes in clearance of up to 10-fold have been observed in patients receiving psychotropic medications while on and off of carbamazepine (85) .
Cigarette smoking induces the microsomal enzyme system, including the aryl hydrocarbon hydroxylase enzyme complex, and increases the oral CL of a variety of psychotropic medications (86) (87) (88) (89) . The time to onset of enzyme induction and to peak effect are not clear for smoking, but may resemble the same pattern as that for polycycic hydrocarbon compounds. Smoking and other drug interactions can introduce significant variability into pharmacokinetic data if not adequately controlled. To illustrate, Figure   3 depicts the dosevs Cpss for DOX plus desmethyldoxepin in all patients analyzed from the TDM data base. The moderate coefficient of correlation reported, r2 = 0.506, is typical of published values. If one analyzes a subset of the population who either did not receive concomitant interacting drugs or received only clearance-inhibiting agents, the correlation coefficients are modestly increased: r2 = 0.596, (df = 58, t = 9.172, P <0.0001) and r2 = 0.601 (df = 52, t = 8.769, P <0.0001), respectively. However, if the subpopulation of patients not receiving drugs and who are not smokers is evaluated, the correlation is considerably better r2 = 0.734, (df = 31, t = 9.108, P <0.0001).
In our TDM data base, smoking history is coded for usage pattern (packs per day) . In prior studies, we have attempted to evaluate for the differences in oral CL of psychotropics by excludingoccasional smokers (<one pack per day). Unfortunately, this information was not reliably provided to us by the individuals completing the TDM form for DOX. Despite this limitation, a positive (n = 10) vs negative (n = 10) smoking historysignificantly changed CL rates for oral DOX: 2.50 (SD 1.09) L/min vs 1.51 (SD 0.78), with P <0.05, df = 18, and t = 2.341, in the patient subgroup on CLinhibiting drugs.
Metabolism can be inhibited by either competitive or noncompetitive interactions with the mixed-function oxidase system. In competitive inhibition, the drug acts as an alternative substrate for the enzyme, reducing binding of the cyclic antidepressant. In contrast, substrate binding remains unchanged in the case of noncompetitive inhibition; however, the enzyme is inactivated.
Inhibitors that act through an enzyme system common to the metabolism of numerous drugs, e.g., microsomal cytochrome P450, will affect a large number of medications from a variety of chemical classes. Interacting substances that either bind to the metabolic enzyme or are toxic to the enzyme system manifest changes in CL of TCAs within 24 to 48 h after an effective concentration of the inhibitor is present (e.g., ethanol, cimetidine). However, the time to mximiul inhibition will be slower when the interacting drug acts by decreasing the biosynthesis of the metabolic enzyme (90) .
Among the enzyme inhibitors, cimetidine has been shown to increase the F of IMI from 40.2% to 75.3%, and decrease its systemic CL from 15.1 to 9.0 mlimin per kilogram body weight. This large decrease in CL is due to cimetidine's ability to decrease in addition to its inhibition of microsomal enzymes (91). Cimetidine decreases both the systemic and oral CL of low-extraction drugs to the same extent. Oral CL (which accounts for F) of drugs showing high hepatic extraction tends to decrease 30% to 50% after cimetidine administration, whereas systemic CL decreases by only 15% to 30%. TCA and cimetidine interaction with DOX (92) and AMI (93) has also been reported. Studies of NT are still controversial (94,95) ; however, its major active metabolite, 2-hydroxy NT, was increased in patients to whom cimetidine was co-administered (95) .
Another highly significant drug interaction occursduring the co-administration of TCAs and antipsychotic agents, leading to a mutually competitive inhibition of metabolism (96) (97) (98) . Twice as high a mean Cpss of DM1 was found in patients who were concurrently taking antipsychotics than in those who were not taking these agents (99). Another case report documented a greater than twofold decrease in Cpss of NT when perphenazine was discontinued. While on perphenazine, this case documented Cpss of NT well above the usual therapeutic range (100). Other agents that are likely to increase TCA Cpsa significantly are chloramphenicol and disulfiram.
In contrast to cimetidine or antipsychotics, disulfiram inhibits a number of enzymes, including alcohol dehydrogenase, dopamine beta-hydroxylase, xanthine oxidase, and the cytochrome P-450 system. Chloramphenicol inhibits cytochrome P-450 in a noncompetitive manner and may also impair enzyme synthesis. Another antibiotic, erythromycin, binds to the P-450 enzyme system, diminishing its activity. The erythromycin-TCA interaction is ifiustrated in Figure 12 , where a 33% dosage increase of imipramine, from 75 mg/day to 100 mg/day, resulted in a 151% increase in the combined Cpss. The latency of the full interaction effect is demonstrated by the increase in Cpss from the first week to the second week that the patient was receiving erythromycin. Interestingly, this patient's Cpss might not have reached the therapeutic range without the drug interaction.
In addition to significant drug interactions being reported in the literature for individuals, our TDM data for DOX illustrate a significant effect on mean oral CL as a function of drug-interaction status for the population (analysis of variance: P <0.0007, df =3, F = 6.38). Figure 13 depicts the 300 mean oral CL for patients with known interactions, categorized on the basis of the data in Table 6 . Doxepin oral CL in the group on no interacting drugs, 2.91 L/min, is significantly less than the oral CL rate in the group on enzyme inducers, 7.09 L/min (P <0.02, df = 35, t = -2.631), and greater than the CL rate in the group on CL inhibitors, 1.93 Llmin (P = 0.09, df = 61, t = 1.711). A greater than threefold difference in mean oral CL rates is observed between inducers and inhibitors (P <0.0001, df = 32, t = 6.687). The mixed category denotes patients on combinations of agents that both inhibit or increase TCA clearance. The reader will recall from equation 1 that a threefold change in oral CL translates directly to the change in dose needed to maintain the same Cpss. Therefore, a patient who was switched from carbamazepine to erythromycin, for instance, might require up to a threefold dose decrease to keep the Cpss constant. These data do not address possible changes in hydroxylated metabolite concentrations, which might obscure the clinical effects resulting from these drug interactions.
For cyclic antidepressants with well-documented therapeutic Cpss ranges, TDM might be an extremely effective intervention to reduce the potential for toxicity or loss of therapeutic effectiveness, when concomitant medications are added to or deletedfrom a patient's drug regimen. In instances where the interacting drug to be added or deleted possesses psychotropic activity-e.g.,
antipsychotics, alprazolam, and carbamazepine-changes in therapeutic response cannot be solely attributed to the alteration of the drug regimen. Oftentimes, the changes observed in Cpss of the antidepressant might be the important factor accounting for the change in a patient's clinical response and (or) side-effect profile.
Cyclic antidepressant interactions with alcohol are also highly significant. Acute ethanol administration inhibits oxidation indirectly through its metabolite, acetaldehyde, which depletes NADPH. At very high concentrations, ethanol can also be a direct competitive inhibitor of the cytochrome P-450 component of the microsomal system. Ethanol inhibits Phase II biotransformation (i.e., conjugation) by inhibiting UDP glucuronic acid synthesis in addition to Phase I, oxidative processes. Dorian et al. (101) reported that DF values for AMI were dramatically increased during the drug-absorption phase in patients who had recently ingested alcohol, resulting in a free AUC increase of 48% ± 13% over an 8-h period. These kinetic changes were accompanied by an impairment in mental functioning. Conversely, chronic ethanol exposure results in enzyme induction if hepatic cirrhosis has not occurred. Ciraulo et al. (102) compared the pharmacokinetics of IMI with clinical response in depressed alcoholic and nonalcoholic patients. Lower Cpss and higher CL rates were found in the alcoholic group. These lower Cpss were associated with less improvement, as assessed by the Hamilton Depression Rating Scale.
Concomitantly administered drugs and (or) alcohol can alter synthesis or elimination of endogenous or exogenous binding compounds, e.g., aj-glycoprotein and cholesterol, leading to changes in V and tissue concentrations (52). This in turn may result in a decrease, increase, or no change in the cyclic antidepressant's CL, depending upon V, E, Q,and CLj0 (see Table 5 ). If binding compound concentrations are significantly altered, then D might differ sufficiently from the normative population of patients used to define CP vs response relationships that TDM data might be difficult to interpret.
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Pharmacogenetics of the Metabolism of Antidepressants Several distinct genetic polymorphisms of metabolism for antidepressants have been described, characterized by a deficiency of a specific enzyme of the cytochrome P-450 system in the liver. About 5% to 10% of the population displays an inherited deficiency in oxidative hydroxylation as determined by the debrisoquine test. An analysis of debrisoquine and its hydroxylated metabolite concentrations in urine are converted to a ratio, which characterizes a patient's enzyme phenotype. Cyclic antidepressanta such as AM!, DM1, and NT have been shown to be under the same genetic control. In a group of volunteers given a single oral dose of AM! and subjected to the debrisoquine test, poor metabolizers of debrisoquine were found to have higher levels of AM! and NT (103) . Highly significant correlations between the debrisoquine ratio and the CP of NT (but not AMI) are reported. Amitriptyline's main metabolic pathway is N-demethylation, which is genetically independent of the debrisoquine-hydroxylator phenotyping. Similar correlations have also been demonstrated with DM1 (104) . One clinical implication of this genetic hydroxylation deficiency that has been suggested (14) is an altered risk for toxicity. Enzyme saturation could occur at lower DM1 concentrations in slow hydroxylators, resulting in greater ratios of parent to hydroxy CP (71). Saturability of the hydroxylator system also explains why some drugs reliably interfere with the metabolism of TCAs. Thioridazine and other phenothiazines, which are competitive inhibitors of hydroxylation (105) , have been shown to significantly increase DM1 CP (106) . was not available for 26% of the patients in the TDM data base, decreasing the power of our observations. Also, an inadequate number of patients had their racial background documented in the DOX data base, precluding analysis.
Pharmacokinetics in the Elderly
The effects of age on drug biotransformation and excretion can be of clinical significance for drugs with a low therapeutic index. Clearance of drugs via the cytochrome P-450 system may be reduced with advancing age, secondary to decreased metabolic capacity of the liver enzyme system and (or) decreased hepatic blood flow, leading to possibly increased side effects and toxicity. Decreases in glomerular filtration rate with age can also explain the observed increases in unconjugated hydroxy TCA metabolite CPs in the elderly. During chronic therapy with DM1, elderly patients were noted to have greater concentrations of 2-hydroxy DM1 than did younger patients. There was no statistical difference in DM1 CP (111). In another study, DM1 CP were reported not to increase with age, suggesting that there were no age-related decreases in oral hydroxylation of the parent compound (112). However, changes in V and oral CL were not completely evaluated.
Cyclicantidepressants, having a large E, will demonstrate a decreased CL, leading to increased Cpss from agerelated reductions in hepatic blood flow. In contrast to Cutler and Kitanaka (111, 112), other studies evaluating the disposition of these agents in the elderly suggest that Cpss of AM!, DM1, JMI, and NT are increased during chronic therapy (23, 113) . After single oral doses, both NT and AM! were found to demonstrate decreased oral CL in the elderly compared to young controls (49,114). In a study comparing IMI disposition in elderly vs young volunteers receiving either intravenous or oral IMI in single doses, the t was found to be markedly prolonged both in elderly males (28.6 vs 16.5 h) and females (30.2 vs 17.8 h) (115). These increases in t1 were due to decreased CL, no change in V being observed. T was shorter in older women than in younger women, but not different for men. Maximum CPs were greater in the elderly of both sexes (males: 40.2 vs 19.5 ng/mL; females: 44.7 vs 10.4 ng/mL). No difference in absolute F was found between the elderly and young of either sex. This study (115) also evaluated DM1 pharmacokinetic parameters but did not find any differences in older vs younger women for t or oral CL. Elderly males demonstrated a significantly longer t for DM1 than did younger men. The rate of metabolism of IMI by demethylation appears to be more sensitive to the effects of age than DM1, for which the major metabolic pathway is hydroxylation (115) .
Similarly, our TDM data for DOX support an age-related effect on oral CL Cpss. Figure 14 demonstrates a weak but significant decline in oral CL vs age: r2 = 0.164 (df = 58, t = 3.340, P <0002). Note that a large number of our patients on DOX are elderly, whereas the population on IMI is, on the average, much younger. Significant differences in the oral CL of DOX are observed when the population is divided into two groups by age, >55 (n = 40) vs 55 There are only a few published pharmacokinetic studies in children with regard to cyclic antidepressants. In general, the child has an increased hepatic surface area and body weight relative to the adult. Children also have proportionately more lean body mass than do adults, sothat less drug might distribute into fatty tissue (116). In late infancy and childhood, many drugs are eliminated via hepatic metabolism at greater rates than in adults. Similar to adults, wide interindividual variation in rates of elimination are observed. In pre-adolescent children the t of IMI is 6 to 15 h, requiring two or more divided daily doses to minimize differences in peak vs trough CP. A higher Cpssratio of DM1 to IMI was also noted in children relative to adults (117) .
Cyclic antidepressants are less highly protein bound in children than in adults. Imipramine binding in cord and adult plasma have been found to average 74% and 86%, respectively, or a 26% f in the neonate vs 14% f in the adult. The binding values for seven-to 10-year-old children are intermediate between those found in the neonate and adults (118). These factors help to explain why a lower CP is sufficient for a therapeutic response in children, e.g., a proposed therapeutic range of 125-250 ng/mL for IMI.
Methodological Approaches for Kinetic Studies
Traditional definitive pharmacokinetic studies designed to evaluate drug interactions require intensive venipuncture, with use of a carefully controlled approach to standardize all aspects of the methodology. Typical data analysis requires a two-step approach: determine the kinetic parameters in each patient and then calculate the population mean and standard deviation. In contrast, population parameter estimation, using the program NONMEM (Nonlinear mixedeffects modeling), allows for a one-step analysis of data, combining all subjects' data into a single regression incorporating relevant physiological variables (age, weight, smoking, drug interactions). In the NONMEM program an extended least-squares approach is used to estimate a maximumlikelihood function.
This method provides estimates of kineticparameters by modeling fixed and random effects. Identification of potential sources of interindividual and intra-individual (residual) variability can result in an extremely sophisticated stepwise approach to kinetic model building (119) . The population-parameter estimation method allows for increased flexibility in data-collection procedures, usually facilitating a more naturalistic study design.
Moreover, retrospectively collected data can be analyzed in this fashion, so long as detailed dosing histories relative to CP are documented along with relevant physiological variables. A third method of data analysis, the "naive pooled data method," can be used if a sufficiently large number of patients is available. The retrospective TDM information presented in this paper uses this third approach (120).
To illustrate the utility of the population-parameter estimation approach, we undertook a prospective controlled trial in collaboration with a multicenter consortium from the University of Missouri Kansas City and the University of Tennessee (sponsored by The Upjohn Company). The study evaluated the pharmacokinetic interaction between alprazolam and IMI in patients with major depressive disorder. The interaction was evaluated by a traditional multiple-dose study design with intensive sampling at steady state during dosing with IMI alone and with concomitant administration of alprazolam (121). The study was designed to permit assessment of the clinical significance of the interaction through side-effect and behavioral evaluations. Population pharmacokinetic analysis, for comparison with the traditional method, was based on additional CPs obtained before and after addition of alprazolam (122).
The AUC for IMI treatment alone was determined by intensive interval sampling on study day seven (prior to alprazolam). 1 mg/day, was then added to the subjects' treatment and the dose was increased by 1 mg/day every three to four days up to a maintenance dose of 4 mg/day. A repeatAUC was then obtained. An additional 19 subjects (total = 29) also had CP measured at flexibly scheduled times as outpatients for the population-parameter estimation component of the study. Nine CPs were obtained, on the average, from each of the 29 patients for population-parameter estimation. In contrast to the AUC study, these CPs were obtained periodically (but not strictly controlled for time of day or specific study day) while off and then on various doses of alprazolam, up to 4 mg/day. Careful record keeping by patients for dosing history was required.
When alprazolam was co-administered with IM1, statistically significant increases in IMI CP were observed at most sampling times. In the 10 traditionally studied patients, the following Cpav were found: pre-alprazolam treatment, IM1 = 43.9 and DM1 = 72.2 ng/mL and on 4 mg/day alprazolam, IMI = 57.6 and DM1 = 86.7 nglmL. These higher IM1 concentrations resulted in a 31% increase in the mean Cpav, a 21% increase in Cp,,, and a 36% increase in Cp,,. Mean IMI CL decreased by 20.8% during therapy with alprazolam. No statistically significant differences ink or V were observed.
The results from the traditional AUC method agreed well with the NONMEM population pharmacokinetic estimation of parameters (121, 122). Oral IMI CL from the populationparameter analysis was estimated to be 1.5 (SD 0.14) L'h per kilogram body weight vs the traditional oral CL of 1.49 (SD 0.36). Volume of distribution, estimated from the population analysis, was 21.611kg vs 18.711kg by the traditional kinetic approach. Using the alprazolam Cp1,av of 44 ng/mL from the AUC data, the population-parameter-estimated kinetic model yielded a predicted IMI CL of 1. 
Summary
TDM for cyclic antidepressants is an important advance towards the goal of optimizing the treatment of depression. Significant inter-and intra-individual variability in pharmacokinetic parameters is observed, owing to exogenous and endogenous factors. Drug interactions, smoking, concurrent disease states, physiological processessuch as aging and renal function, and demographics all can affect the kinetic profile of cyclic antidepressants. Changes in oral CL caused by these variables translate directly to changes in a patient's drug concentration in plasma. If, as is the case for many TCAs, a therapeutic range can be defined, then TDM can significantly improve the likelihood of good response in individuals. Pharmacokinetic principles defining and explaining the determinants of oral CL can give the clinician greater insight into the reasons for therapeutic failure and for toxicity. New cyclic antidepressants, for the most part, resemble the older TCAs in their pharmacokinetics. Therefore, much of the reported research with the TCAs can be (cautiously) applied to many of the newer cyclic compounds.
Clinical impact studies evaluating the pharmaco-economics of TDM are needed. The data analyzed to date for our TDM program for patients in The Texas Department of Mental Health and Mental Retardation facilities suggest clinical benefit. Figure 15 illustrates the mean Cpss for IMI plus DM1, by facility. The mean Cpss are significantly greater in those three facilities where clinical pharmacy and psychopharmacology consultation services are available. The mean Cpss for these three facilities are within the usual range suggested for optimal response. In contrast, the mean Cpss at all the other facilities combined is below the usual therapeutic range. Therefore, the availability of analytical capabilities is not sufficient per se to appreciably alter drug use unless a monitoring program is also established to interpret the CPa and standardize the process by which these concentrations are measured.
Areas of research requiring additional study include the role of free-drug concentration monitoring, the importance of the hydroxylated metabolites, pharmacodynamic modeling with use of time-dependent multivariate methods, and pharmaco-economic impact studies evaluating the potential differences in cost of care among the various dosing methods: empirical dose titration vs TDM vs single-test-dose vs Bayesian dose forecasting.
NONMEM
analysis of patients' data can result in the development of superior models to predict an individual's CL. Bayesian dose forecasting utilizes population-parameter-estimated parameters to develop a physiological model incorporating intra-individual and interindividual sources of variability into its dosage recommendations (123, 124).
